Abiopharma

TransUnion Declares First Quarter 2026 Dividend of $0.125 per Share

Skeena Gold & Silver Releases 2025 Sustainability Report Entitled ‘Where Voices Meet, Progress Follows’

Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

New Form 424B2 - UBS AG <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001839882-26-023877 <b>Size:</b> 1 MB

New Form SCHEDULE 13G/A - Silicon Valley Acquisition Corp. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001167557-26-000057 <b>Size:</b> 10 KB

New Form SCHEDULE 13G - PRESIDIO PRODUCTION Co <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0000919574-26-002952 <b>Size:</b> 17 KB

New Form 424B2 - UBS AG <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001839882-26-023876 <b>Size:</b> 1 MB

New Form SCHEDULE 13G - Lafayette Digital Acquisition Corp. I <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001104659-26-059886 <b>Size:</b> 29 KB

New Form 424B2 - UBS AG <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001839882-26-023875 <b>Size:</b> 749 KB

New Form SCHEDULE 13G - PALOMA ACQUISITION CORP I <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0000919574-26-002951 <b>Size:</b> 16 KB

Net Asset Value(s)

Pfizer Inc. - European Commission ApprovesPfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

New Form 424B2 - CITIGROUP INC <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001918704-26-012865 <b>Size:</b> 672 KB

New Form 424B2 - UBS AG <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001839882-26-023873 <b>Size:</b> 859 KB

New Form SCHEDULE 13G - Opus Genetics, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0000919574-26-002950 <b>Size:</b> 16 KB